米非司酮联合消瘤方对子宫肌瘤气滞血瘀证患者血液流变学及GPR30-EGFR信号通路的影响

doi:10.20047/j.issn1673-7210.2023.09.06

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (759 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effects of Mifepristone combined with Xiaoliu Prescription on clinical efficacy, hemorheology, and GPR30-EGFR signaling pathway in intermyowall uterine fibroids patients with syndrome of qi stagnation and blood stasis. Methods Eighty intermyowall uterine fibroids patients with syndrome of qi stagnation and blood stasis admitted to the First Affiliated Hospital of Yunnan University of Chinese Medicine from December 2021 to March 2022 were selected and divided into control group (40 cases) and experimental group (40 cases) according to random number table method. The control group was treated with Mifepristone, and the experimental group was treated with Mifepristone combined with Xiaoliu Prescription. The treatment course of both groups was three months (withdrawal of the drug during menstrual period). The clinical efficacy and uterine volume, fibroid area, hemorheology indexes before and after treatment were compared between the two groups. Real-time quantitative PCR and Western blot were used to detect the mRNA and protein expression levels of G-protein-coupled receptor 30 (GPR30) and epidermal growth factor receptor (EGFR) in two groups. Results Four cases fell off in the experimental group. In the control group, five cases were shed and one case was eliminated. The clinical effect of experimental group was better than that of control group (P＜0.05). After treatment, uterine volume, fibroid area, and plasma viscosity in two groups were lower than those before treatment, and experimental group was lower than control group (P＜0.05). After treatment, the whole blood high and low shear viscosity values of experimental group were lower than those of experimental group before treatment and control group (P＜0.05). After treatment, the mRNA and protein expression levels of GPR30 and EGFR in experimental group were lower than those in control group (P＜0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05). No abnormal changes of liver and kidney function were observed in both groups during treatment. Conclusion Mifepristone combined with Xiaoliu Prescription can effectively treat intermyowall uterine fibroids, reduce uterine volume and uterine fibroid area, improve hemorheology indexes, reduce GPR30 and EGFR expression, with high safety.

Key words： Uterine Fibroids Hemorheology G-protein-coupled receptor 30 Epidermal growth factor receptor Integration of traditional and western medicine

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Qin1 RUAN Chengjuan2 ZHANG Ruiwen2 ZHANG Yanni2 CHEN Dongqiong3▲

Cite this article:

LI Qin1 RUAN Chengjuan2 ZHANG Ruiwen2 ZHANG Yanni2 CHEN Dongqiong3▲. Effects of Mifepristone combined with Xiaoliu Prescription on hemorheology and GPR30-EGFR signaling pathway in uterine fibroid patients with syndrome of qi stagnation and blood stasis[J]. 中国医药导报, 2023, 20(9): 33-37.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.09.06 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I9/33

[1] Ciebiera M，W?覥odarczyk M，Zgliczyński S，et al. The Role of miRNA and Related Pathways in Pathophysiology of Uterine Fibroids-From Bench to Bedside [J]. Int J Mol Sci，2020，21（8）：1-26.
[2] Giuliani E，As-Sanie S，Marsh EE. Epidemiology and management of uterine fibroids [J]. Int J Gynaecol Obstet，2020， 149（1）：3-9.
[3] 史莎莎，余成浩.子宫肌瘤的治疗进展[J].中国妇幼保健，2020，35（16）：3122-3125.
[4] 毛春仙，蔡蓉蓉，王秀萍，等.桂枝茯苓胶囊配伍米非司酮治疗绝经前期子宫肌瘤的疗效观察[J].中华中医药学刊，2012，30（3）：665-667.
[5] 谢幸，苟文丽.妇产科学[M].北京：人民卫生出版社，2013：310-313.
[6] 中华中医药学会.中医妇科常见病诊疗指南[M].北京：中国中医药出版社，2012：127-128.
[7] 康媛，崔亚杰，李佩，等.TVH、TLH、TAH对子宫肌瘤患者性功能和卵巢功能的影响对比[J].中国妇产科临床杂志，2019，20（1）：16-18.
[8] 肖颖丽，白秀萍.子宫肌瘤的非手术治疗进展[J].中国实用妇科与产科杂志，2002，18（12）：60-62.
[9] 吕丽华，孙娇.消癓汤联合米非司酮对子宫肌瘤患者的疗效及性激素水平和凝血指标的影响[J].血栓与止血学，2022，28（3）：929-931.
[10] 孙颖.米非司酮联合血府逐瘀颗粒治疗子宫肌瘤临床疗效[J].辽宁中医杂志，2022，49（3）：130-133.
[11] 刘照龙，卞海艳，白金录，等.黄郁蛭瘤方联合米非司酮治疗气滞血瘀型子宫肌瘤疗效及对卵巢功能、VEGF水平的影响[J].现代中西医结合杂志，2022，31（6）：796-799.
[12] 谈勇.中医妇科学[M].北京：中国中医药出版社，2016：253-254.
[13] 易修珍.扶正祛邪破解妇科疑难顽症：易修珍学术思想与临床经验集[M].北京，中国中医药出版社，2015：107-108.
[14] 王莉琳，时燕萍.子宫肌瘤的血液流变学应用探讨[J].中华中医药学刊，2010，28（11）：2409-2411.
[15] 陈可冀.血瘀证与活血化瘀治疗的研究[J].中国中医药现代远程教育，2005，3（11）：10-12.
[16] 李玉芬，戚其学.150例高血压病患者血液流变学指标变化及其临床意义的研究[J].中国血液流变学杂志，2014， 23（1）：127-129.
[17] 程显杰，何作云，杜保琳.子宫肌瘤血液流变特性及其意义初探[J].中国血液流变学杂志，1995（1）：8-10.
[18] 王莉琳，时燕萍.子宫肌瘤的血液流变学应用探讨[J].中华中医药学刊，2010，28（11）：2409-2411.
[19] 于强，李祚雯，孙圣荣.绝经后乳腺癌患者癌组织中雌激素受体GPR30、MMP9表达及临床意义[J].临床和实验医学杂志，2022，21（11）：1193-1196.
[20] 刘欣悦，张裕民，张萍.GPER在女性相关恶性肿瘤中作用的研究进展[J].大连医科大学学报，2022，44（3）：249-254.
[21] 申亚辉，马艳华.G蛋白偶联受体30/表皮生长因子受体信号通路对女性生殖系统影响的研究进展[J].中国计划生育和妇产科，2021，13（10）：33-38.
[22] Hofmann GE，Rao CV，Barrows GH，et al. Binding sites for epidermal growth factor in human uterine tissues and leiomyomas [J]. J Clin Endocrinol Metab，1984，58（5）：880-884.
[23] 卢清.GPR30-EGFR信号通路在双酚A促子宫肌瘤细胞增殖中的作用[D].南京：东南大学，2016.
[24] 袁瑞利，平毅，黄玲玲，等.GPR30在妇科疾病中的研究进展[J].医学综述，2019，25（8）：1480-1484.
[25] Liu J，Yu L，Castro L，et al. A nongenomic mechanism for“metalloestrogenic”effects of Cadmium in human uterine leiomyoma cells through G protein-coupled estrogen receptor [J]. Arch Toxicol，2019，93（10）：2773-2785.